LLPA
5.5.2021 15:02:09 CEST | Business Wire | Press release
The Leading Learning Partners Association (LLPA), an international association of 32 members across 55+ countries, have successfully hosted a series of C3 cloud skills tour events in over 17 countries in a virtual setting since January 2021.
We recognize that transformation to cloud technologies requires skills transformation and most importantly, that digital transformation is about people. During this event, The LLPA in close cooperation with Microsoft and other key partners provide business leaders, executives, IT professionals, developers and Microsoft Azure consultants, an opportunity to gain valuable insights and learn from local and international leading industry experts on topics such as building high-performance teams and better ways of leveraging existing and future cloud investments. This exciting global tour is famous for bringing learning thought leaders, executives, and partners, together to collaborate and share best practices.
“Leading transformation starts with an idea, a vision and the ability to identify expectations. For this you must be informed, knowledgeable, and equipped. The sphere of cloud technology is robust and ever changing. We’re inviting IT professionals and leaders everywhere, to attend the final C3 Global Cloud Skills Tour event to gain knowledge from leading experts that will help organizations of all sizes build a future-ready workforce” says Patrick Kersten, Chairman of the Board at LLPA.
“Contrary to popular belief, digital transformation is less about technology and more about people. You can pretty much buy any technology, but your ability to adapt to an even more digital future depends on developing the next generation of skills, closing the gap between talent supply and demand, and future-proofing your own and others’ potential” – Harvard Business Review. The C3 Global Cloud Skills Tour aims to address the cloud skills gaps by ensuring all existing and future cloud customers have the technical and soft skills needed to be successful.
The LLPA will host this live 2-day event 9-10 June 2021 from 9-1pm CET joined by international speakers, Ken Taylor , President – Training Industry, Inc., Kåre Nygård , Head of Digital Consulting Norway – TietoEVRY, Mohanna Azarmandi , Chief Learning Officer – Microsoft, Jayne Groll , CEO – DevOps Institute and many others. The LLPA have more than 15 live and on-demand sessions planned, ranging from technical deep dives to digital transformation and skilling best practice sessions. We also have a great panel discussion lined up led by leading training providers from multiple regions.
“We need to adjust and embrace a more virtual way of living and more than ever it is vital that people remain closely connected. It is great to see that the global network of the Leading Learning Partner Association is showing leadership to deliver 100% virtual trainings to support our mutual customers in the continuation and acceleration of their skilling efforts to support their digital transformation strategy. These efforts have been recognized by our mutual customers and Microsoft awarded the Leading Learning Partners Association with a global Learning Partner of the year award, for their continuous commitment for accelerating cloud skills.” – Geoff Hirsch, Senior Director of Partner Channel, WW Learning & Readiness at Microsoft.
About The LLPA
Born in the Netherlands in 2013, the Leading Learning Partners Association (LLPA) is a global organization with a member presence in more than 55 countries. Our mission is to be THE global cloud skills services organization, dedicated to providing the right tools, learning resources and services at the right time to ensure cloud skills are accessible to anyone and everyone at any time across the globe.
Our extensive network of trusted members contributes to the development of expert job-ready industry professionals through hybrid learning offerings, consulting, and certification. Together, our members have trained over 500,000 students per year, covering more than 90% of the European GDP. The LLPA has been a Microsoft Partner since 2013 and awarded Microsoft Learning Partner of the Year 2020.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210505005442/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
